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Abstract
Gene-regulatory network analysis is a powerful approach to elucidate the molecular processes and 
pathways underlying complex disease. Here we employ systems genetics approaches to 
characterize the genetic regulation of pathophysiological pathways in human temporal lobe 
epilepsy (TLE). Using surgically acquired hippocampi from 129 TLE patients, we identify a gene-
regulatory network genetically associated with epilepsy that contains a specialized, highly 
expressed transcriptional module encoding proconvulsive cytokines and Toll-like receptor 
signalling genes. RNA sequencing analysis in a mouse model of TLE using 100 epileptic and 100 
control hippocampi shows the proconvulsive module is preserved across-species, specific to the 
epileptic hippocampus and upregulated in chronic epilepsy. In the TLE patients, we map the trans-
acting genetic control of this proconvulsive module to Sestrin 3 (SESN3), and demonstrate that 
SESN3 positively regulates the module in macrophages, microglia and neurons. Morpholino-
mediated Sesn3 knockdown in zebrafish confirms the regulation of the transcriptional module, and 
attenuates chemically induced behavioural seizures in vivo.
Epilepsy is a serious neurological disorder affecting about 1% of the world’ s population. 
Recently, a growing body of experimental and clinical data has implicated Toll-like receptor 
(TLR) signalling1 and release of proconvulsant inflammatory molecules (that is, interleukin 
(IL)-1Ś) in both seizure generation and epileptogenesis2,3. However, the pathogenetic 
mechanisms linking these inflammatory processes with the development (and recurrence) of 
epileptic seizures in humans are unclear. Despite high heritability of epilepsy4–6, both 
genome-wide association studies (GWAS) and exome sequencing approaches have so far 
provided limited insights into the genetic regulatory mechanisms underlying inflammatory 
pathways in epilepsy aetiology7–11, and traditional single-variant association approaches are 
likely to be underpowered to detect complex gene network interactions that underlie disease 
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susceptibility12. As the molecular processes driving complex disease usually affect sets of 
genes acting in concert, one alternative strategy is to use systems-level approaches to 
investigate transcriptional networks and pathways within pathologically relevant cells and 
tissues13,14. Integrated analysis of transcriptional networks with genetic susceptibility data 
and phenotypic information allows specific transcriptional programmes to be connected to 
disease states, and thereby can identify disease pathways and their genetic regulators as new 
targets for therapeutic intervention15.
Almost uniquely among disorders of the human brain, epilepsy surgery offers opportunities 
for gene expression profiling in ante-mortem brain tissue from pathophysiologically relevant 
brain structures such as the hippocampus16. This allows direct investigation of 
transcriptional programmes in brain tissue from living epilepsy patients. In this study, we 
integrate unsupervised network analysis of global gene expression in the hippocampi of 
patients with temporal lobe epilepsy (TLE) with GWAS data in a systems genetics 
approach17. We uncover pathways and transcriptional programmes associated with epilepsy 
that are conserved in mouse epileptic hippocampus, including a proconvulsant gene network 
encoding IL-1Ś3 and TLR-signalling genes1 previously implicated in epilepsy. Using 
genome-wide Bayesian expression QTL mapping18, we probe the genome for key genetic 
regulators of the network in human brain. We pinpoint an unexpected gene, Sestrin 3 
(SESN3) whose protein product controls the intracellular response to reactive oxygen 
species19–22, as a trans-acting genetic regulator of the proconvulsant gene network in the 
human epileptic hippocampus. We carry out validation experiments in independent in vitro 
and in vivo systems, which confirm the genetic regulation of the proconvulsant 
transcriptional programme in epilepsy by Sestrin 3, therefore providing a first evidence of a 
function for SESN3 in disorders of the human brain.
Results
Identification of a gene network associated with epilepsy
We first assessed the degree of variation in gene expression between hippocampal subfields 
in TLE patients with hippocampal sclerosis, and compared this with the total variation in 
gene expression measured both across subjects and between subfields (Supplementary Fig. 
1). We found higher variability in gene expression across TLE subjects than between the 
hippocampal subfields alone, suggesting that variation in whole hippocampus expression 
can be used to infer co-expression networks in the hippocampus of TLE patients 
(Supplementary Fig. 1). After excluding subjects with incomplete clinical data or 
nonhippocampal sclerosis pathology, whole-genome expression profiles in surgically 
resected hippocampi from 129 TLE patients (median age at surgery 35 years, range 1–64 
years, male/female ratio of 1.2:1; Supplementary Table 1) were available for gene co-
expression network analysis.
We then investigated whether the transcriptome in the hippocampus of these 129 TLE 
patients is organized into discrete gene co-expression networks, and if these have functional 
implications for susceptibility to epilepsy. Gene co-expression networks were reconstructed 
genome wide using Graphical Gaussian Models (GGMs)23, which identified a large co-
expression network comprising 442 annotated genes (false discovery rate (FDR)<5%, Fig. 
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1a and Supplementary Data 1). To investigate whether the protein products of the TLE-
hippocampus derived transcriptional network (TLE-network) genes have a shared function 
at the protein level, we used the DAPPLE algorithm24. This method interrogates high-
confidence protein–protein interactions to assess the physical connections among proteins 
encoded by the genes in the network. Genes comprising the TLE-network were found to 
have increased protein–protein interconnectivity as compared with random protein–protein 
interaction networks (P = 9.9 × 10−5, Supplementary Fig. 2). This provides evidence that 
proteins encoded by the co-expressed genes in the TLE-network interact physically, 
supporting the validity of the gene network topography.
As gene expression may vary both as a cause and a consequence of disease, we investigated 
the causal relationship between the TLE-network and epilepsy by integration with genetic 
susceptibility data. Here, DNA variation was used to infer causal relationships between the 
network and epilepsy by assessing whether the network as a whole was genetically 
associated with epilepsy. To this aim, we used focal epilepsy GWAS data6,25 from a 
separate cohort of 1,429 cases (consisting mainly of patients with TLE) and 7,358 healthy 
controls. Although no single-nucleotide polymorphism (SNP) achieved genome-wide 
significance in the epilepsy GWAS (Supplementary Fig. 3), we found that the TLE-network 
as a whole was highly enriched for genetic associations to focal epilepsy compared with 
genes not in the network (P = 2 × 10−7; Fig. 1a and Supplementary Table 2). These 
integrated analyses of co-expression network and genetic susceptibility data from a focal 
epilepsy GWAS provide independent evidence to support the causal involvement of the 
TLE-network in epilepsy aetiology.
Conservation and functional specialization of the network
The TLE-network was significantly enriched for genes belonging to several biological 
pathways involving cell-to-extracellular matrix adhesion including ‘ extracellular matrix–
receptor interaction’  (P = 3.9 × 10−5), ‘ focal adhesion’  (P = 1.4 × 10−4) and inflammation, 
such as the ‘ cytokine–cytokine receptor interaction’  (P = 2.4 × 10−5) and ‘ TLR signalling’  
(P = 3.9 × 10−5; Fig. 1b). The observation that the TLE-network was enriched for multiple 
pathways led us to investigate whether the network contained functionally homogenous 
transcriptional modules (that is, sub-networks of highly correlated genes) with implications 
for epilepsy aetiology. Using unsupervised agglomerate clustering approaches (see 
Supplementary Methods), we identified two transcriptional modules comprising 69 
(Module-1) and 54 (Module-2) unique genes, respectively (Fig. 1c and Supplementary Data 
1). Module-1 was specifically enriched for gene ontology categories related to inflammatory 
mechanisms, whereas Module-2 was enriched for cell-to-extracellular matrix adhesion 
processes (Fig. 1d and Supplementary Table 3), indicating functional sub-specialization 
within the larger TLE-network. We observed that Module-1 genes were significantly 
upregulated as compared with genes in the larger TLE-network, Module-2, or with respect 
to all other genes profiled in the hippocampus of TLE patients (Fig. 1e). This increased 
hippocampal expression of Module-1 genes in TLE patients was not observed in separate 
gene expression data sets from the hippocampus of healthy subjects (that is, individuals 
clinically classified as neurologically normal; Supplementary Fig. 4). Notably, Module-1 
was markedly enriched for highly expressed inflammatory cytokines (16-fold enrichment, P 
Johnson et al. Page 4
Nat Commun. Author manuscript; available in PMC 2015 October 30.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
= 6.6 × 10−13) many of which belong to the IL-1 signalling cascade (IL-1Ś, IL-1RN, IL-1ř, 
TNFř) and the TLR-signalling pathway (11-fold enrichment, P = 1.4 × 10−6), previously 
implicated in epileptogenesis1 and brain inflammation2,3 (Supplementary Fig. 5). Taken 
together, these data indicate the presence of a coordinated transcriptional programme 
(Module-1), encompassing TLR activation and release of proinflammatory cytokines 
(including IL-1Ś), in chronic human epileptic hippocampus as previously hypothesized3,26.
We then investigated whether the TLE-network and Module-1 genes, in particular, were 
conserved across-species and to this aim we carried out high-throughput sequencing of 
mRNA (RNA-Seq) in whole hippocampus from 100 epileptic (pilocarpine model)27 and 100 
control naïve mice (full details of this model are reported in the Supplementary Methods). 
We employed GGMs to assess the co-expression relationships between the 371 mouse 
orthologues of the human TLE-network genes, and found that 312 genes (84%) had 
significant co-expression (FDR<5%) with at least another network gene in mouse epileptic 
hippocampus (Fig. 2a). The conserved TLE-network genes formed 1,119 significant partial 
correlations in mouse epileptic hippocampus, which is significantly higher than expected by 
chance (P = 0.001 by 10,000 bootstrap permutations; Fig. 2b). In contrast, only 615 
significant partial correlations between the same 312 genes were detected in healthy 
hippocampus (P = 0.659 by 10,000 bootstrap permutations), suggesting that the TLE-
network is specifically conserved in the epileptic mouse hippocampus (Fig. 2b). In keeping 
with the high expression of proinflammatory genes observed in the hippocampus of TLE 
patients (Supplementary Fig. 5), the mouse orthologues of Module-1 genes that were 
significantly upregulated in epileptic hippocampus were enriched for TLR-signalling and 
cytokines (gene set enrichment analysis28, P = 9.03 × 10−4, Fig. 2c). These comparative 
genomics analyses revealed that, to a large extent, the hippocampal TLE-network is 
conserved across-species, and confirm that genes for TLR signalling and proinflammatory 
cytokines within the TLE-network are upregulated in chronic epileptic hippocampus.
SESN3 is a genetic regulator of the proinflammatory network
We set out to identify genetic variants that regulate the gene co-expression modules (that is, 
regulatory ‘ hotspots’ ) by employing genome-wide Bayesian expression QTL mapping 
approaches18,29. To this aim, we have developed a multi-step strategy to identify SNPs that 
regulate the expression of a transcriptional module (or network) as a whole. As first step, we 
summarize the expression of the genes in each module using principal component (PC) 
analysis and detect regulatory ‘ hotspots’  using a Bayesian regression model at the genome-
wide level29. This analysis prioritizes genomic regions associated with variation in mRNA 
expression of the genes in each module. As a second step, to refine the genetic mapping 
results, we regress jointly the mRNA levels of module genes to all SNPs within the 
regulatory locus identified in the first step18. Given the functional specialization within the 
large TLE-network (Fig. 1d), we investigated the genetic regulation of both Module-1 and 
Module-2, by analysing 527,684 genome-wide SNPs in the TLE patient cohort. In the first 
step, we identified a single locus on chromosome 11q21 centred on SNP rs10501829, which 
was significantly associated with the first PC of Module-1 expression (FDR<5%; Fig. 3a). 
Module-2 showed no significant genome-wide associations (Supplementary Fig. 6). In the 
second step, we investigated in detail the locus on chromosome 11q21 regulating Module-1 
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and carried out joint mRNA levels-SNPs analysis of all genes in Module-1 and all SNPs 
genotyped within a 1-Mbp region centred on SNP rs10501829. This analysis identified three 
additional SNPs (rs530190, rs7107661 and rs6483435) in the Best Model Visited (that is, 
the best combination of SNPs predicting mRNA level of module genes, see Supplementary 
Methods) that were associated with the majority of genes of Module-1 (58–74% of 
Module-1 genes are predicted by individual SNPs, Fig. 3b). The set of SNPs regulating in 
trans the expression of Module-1 genes defined the boundaries of a minimal regulatory 
region spanning ~383 kb (Fig. 3b).
The larger 1-Mbp region centred on SNP rs10501829 contained eight annotated protein-
coding genes (Fig. 3b). To further prioritize candidate genes, we carried out co-expression 
analysis between each of these genes and all genes in Module-1, and found that Sestrin 3 
(SESN3) was, on average, most strongly and positively correlated with Module-1 gene 
expression (P = 1.7 × 10−13, Fig. 3c). The positive association between SESN3 and 
Module-1 gene expression remained significant following genome-wide correlation analysis 
in human hippocampus (P < 0.00001, Supplementary Fig. 7). In summary, SESN3 is the 
only gene within the minimal regulatory region and, when compared with all genes within a 
1-Mbp window around SNP rs10501829, showed the strongest correlation with Module-1 
gene expression. Similarly, in the epileptic mouse hippocampus, we found that increased 
Sesn3 mRNA expression was also significantly associated with upregulation of Module-1 
genes (P = 5.4 × 10−6, Fig. 3d), therefore providing independent, cross-species evidence 
supporting SESN3 as a positive regulator of Module-1 genes in epileptic hippocampus.
Taken together, these data prioritize SESN3 as a candidate gene for the trans-acting genetic 
regulation of Module-1. To test this hypothesis, we first carried out gene knockdown 
experiments followed by transcriptional analysis of Module-1 genes by means of RNA 
interference using short interfering RNA (siRNA). Initially, we used murine bone marrow-
derived macrophages (BMDMs) and BV2 microglia cell line as an in vitro system as 
Module-1 recapitulates the ATF3/AP1 transcriptional complex and IL-1 signalling 
(Supplementary Fig. 8), known to be highly expressed in lipopolysaccharide (LPS)-
stimulated macrophages30. Consistent with the positive correlation of Module-1 genes with 
SESN3 mRNA expression (Fig. 3c,d and Supplementary Fig. 7), we observed decreased 
expression of Module-1 genes after siRNA-mediated knockdown of SESN3 in both LPS-
stimulated BMDMs and BV2 microglia cells (Fig. 4a,b). Similar results were found in 
unstimulated BV2 microglial cells, suggesting that SESN3 can modulate expression of 
proinflammatory genes (for example, IL-1Ś, IL-1RN, IL-1ř, TNFř) even in the absence of a 
strong inflammatory stimulus (Fig. 4c). Within the human brain we localized SESN3 
expression to neurons by immunohistochemistry (Fig. 4d), and found that it is highly 
expressed in the hippocampus of TLE patients as compared with hippocampus from control 
autopsy samples (Fig. 4e and Supplementary Fig. 9). In keeping with this, we found 
increased Sesn3 mRNA expression in the mouse hippocampus after pilocarpine-induced 
status epilepticus (Supplementary Fig. 10), suggesting an association between SESN3 gene 
expression and epilepsy that is conserved across-species. We then tested whether Module-1 
genes are upregulated when SESN3 is overexpressed in neurons. To address this aim, we 
used an integrating lentiviral vector (LV) for gene overexpression in primary murine 
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neurons (see Supplementary Methods) and quantitative PCR analysis showed that the 
relative levels of Sesn3 mRNA were markedly increased in transduced neurons compared 
with the levels observed in mock transduction (Fig. 4f). Consistent with the observed 
positive correlation between increased Sesn3 expression and Module-1 genes in the 
hippocampus (Fig. 3c,d), lentiviral-mediated overexpression of Sesn3 resulted in significant 
upregulation of Module-1 genes in hippocampal neurons (Fig. 4f). These in vitro 
experiments show that Sesn3 is capable of regulating Module-1 gene expression in different 
cell types and in particular of inducing upregulation of proinflammatory genes in 
hippocampal neuronal cells. Our findings in primary neurons are in keeping with previous 
data reporting the activity of several inflammatory molecules in neuronal cells under 
pathological conditions31, including IL-1Ś and its receptor32. Furthermore, the upregulation 
of proinflammatory genes in neurons supports the ‘ neurogenic inflammation’  hypothesis, 
wherein neurons are proposed as triggers of innate and adaptive immune-cell activation in 
the central nervous system (CNS; reviewed in Xanthos and Sandkuhler33).
SESN3 regulates chemically induced behavioural seizures
The in vitro data, combined with the positive association between SESN3 and Module-1 
gene expression in human and mouse epileptic hippocampus, indicate that SESN3 is a 
positive regulator of Module-1. We hypothesized that inhibiting SESN3 would reduce the 
activity of genes in functional pathways enriched in Module-1, including proconvulsant 
signalling molecules, and thus by extension could have seizure-suppressing effects. To test 
this hypothesis in vivo, we investigated the role of SESN3 in a zebrafish model of 
convulsant-induced seizures34,35. In this model, exposure of 2- or 3-day-old zebrafish larvae 
to the convulsant agent pentylenetetrazole (PTZ) rapidly induces the expression of synaptic 
activity-regulated genes in the CNS and causes vigorous episodes of calcium flux in muscle 
cells as well as intense locomotor activity characteristic of epileptic seizures34,35. This acute 
seizure model has been primarily used to investigate the anti-/proconvulsant activity of 
compounds36 and for in vivo drug discovery34. In particular, molecular and behavioural 
phenotypes in the zebrafish PTZ-induced seizure model have been employed to identify 
compounds that attenuate seizure activity37. We employed this model to correlate the 
locomotor responses with gene network dynamics, that is, transcriptional activation of the 
neuronal activity-regulated gene c-fos38 and an additional subset of Module-1 genes in 
response to PTZ treatment in Sesn3 morphant and control morphant larvae. Sesn3 showed 
widespread expression in the brain of 3 and 4 days post fertilization (d.p.f.) zebrafish larvae 
(Supplementary Fig. 11) and, following PTZ treatment, we found that Sesn3 morphant 
zebrafish larvae exhibited significantly reduced locomotor activity as compared with control 
morphant larvae (Fig. 5a). To test the specificity of the morpholino effect, we co-injected the 
Sesn3 morpholinos (Supplementary Fig. 12) along with synthetic Sesn3 mRNA, which 
cannot be targeted by either of the splice-blocking morpholinos (see Supplementary 
Methods), and assessed whether the Sesn3 mRNA could rescue the morphant phenotype. 
We observed an almost complete rescue of the locomotor activity phenotype (only 10% 
difference between uninjected larvae and larvae co-injected with Sesn3 morpholinos and 
Sesn3 mRNA), with no significant differences in the locomotor activities between the 
uninjected larvae and the larvae injected with synthetic Sesn3 mRNA alone (Fig. 5b).
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To further confirm Sesn3-dependent modification of neuronal response to PTZ, we 
measured transcriptional activation of the neuronal activity-regulated gene c-fos, an 
important regulator for cellular mechanisms mediating neuronal excitability and survival38. 
Consistent with the behavioural assay (Fig. 5a), there was decreased expression of c-fos in 
the brain (mostly in forebrain and midbrain) following PTZ exposure in Sesn3 morphant 
larvae as compared with control morphant larvae (Fig. 5c and Supplementary Fig. 12). As 
silencing of Sesn3 resulted in downregulation of Module-1 genes in vitro (Fig. 4a–c), we 
tested whether inhibiting Sesn3 could similarly reduce the activity of Module-1 genes 
following PTZ exposure in vivo. We observed significant reduction in the PTZ-induced 
mRNA expression of Module-1 genes in the Sesn3 morphant as compared with control 
morphant larvae (Fig. 5d), and we also found that transient overexpression of Sesn3 in 
zebrafish larvae increased expression of Module-1 genes independently of PTZ treatment 
(Fig. 5e). Taken together, these data show that Sesn3 knockdown attenuates both PTZ-
induced locomotor convulsive behaviour and the transcriptional responses of c-fos and 
Module-1 genes to treatment with PTZ. These findings in the zebrafish model support the 
evidence from our studies of human and mouse epileptic hippocampus and primary murine 
neurons that SESN3 positively regulates expression of proconvulsive molecules (Module-1 
genes).
Discussion
Deciphering the complex regulatory processes of pathophysiological pathways in human 
brain remains a challenge due to the inaccessibility of ante-mortem tissue but can have 
important mechanistic and therapeutic implications39. In this study, we have used surgical 
hippocampal tissue samples and employed systems genetics approaches17 to investigate 
transcriptional networks for epilepsy and their genetic regulation. We identified a large gene 
co-expression network in the human epileptic hippocampus that was conserved in mouse 
epileptic hippocampus and was enriched for GWAS genetic signals of focal epilepsy. In 
keeping with similar network-based studies of complex disease such as type-1 diabetes40 
and autism spectrum disorder41,42, our approach leverages the combined evidence from 
genetic susceptibility variants across multiple genes15 to link the TLE-hippocampus network 
with susceptibility to focal epilepsy. Within the TLE-network, we identified a functionally 
coherent and coordinated transcriptional programme (Module-1), which was overexpressed 
in the hippocampus of TLE patients, and which encoded epileptogenic IL-1 (refs 2,3,43) and 
TLR-signalling pathways1. We confirmed the upregulation TLR-signalling genes and 
proinflammatory cytokines in chronic epilepsy by RNA-Seq analysis in 200 mouse 
hippocampi. Preclinical studies in experimental models of epilepsy have consistently shown 
that individual proinflammatory cytokines such as IL-1Ś or tumor necrosis factor (TNF)-ř
are overexpressed in brain areas of seizure generation and propagation44. Therefore, 
targeting TLR and IL-1 signalling has been proposed as a possible avenue for therapeutic 
intervention in epilepsy and antiepileptogenesis1,3, including reduction of acute seizures45 
and drug-resistant chronic epileptic activity46. The identification of upstream genetic 
regulators of these pathways in the human epileptic brain might suggest opportunities for 
novel targets for disease modification. To investigate the genetic regulation of the TLE-
network and the proinflammatory module therein, we employed Bayesian expression QTL 
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mapping approaches18, which identified SESN3 as a trans-acting genetic regulator of a 
proinflammatory transcriptional programme in the epileptic human hippocampus. The 
positive regulation of this network by SESN3 was confirmed in vitro across different cell 
types by gene silencing (resulting in ~50% reduction of Module-1 gene expression) and 
overexpression experiments (resulting in approximately two- to sevenfold activation of 
Module-1 genes, Fig. 4), and in vivo using a zebrafish model of chemically induced seizures 
(Fig. 5e).
SESN3 is a member of the Sestrin family of proteins that have been shown to decrease 
intracellular reactive oxygen species and to confer resistance to oxidative stress19. Intrinsic 
antioxidant defenses are important for neuronal longevity and the genes that regulate these 
processes might well influence pathological processes associated with oxidative damage in 
the brain, a common feature of many neurodegenerative diseases including epilepsy47,48. 
Therefore, we hypothesize that SESN3 might regulate neuro-inflammatory molecules, 
previously implicated in epilepsy1,33,43,49, through modulation of oxidative stress in the 
brain.
Our systems genetics analysis in the human hippocampus, combined with in vitro and in 
vivo data, revealed SESN3-dependent regulation of epileptogenic IL-1Ś3 and TLR-signalling 
genes1. The upstream genetic control of the proconvulsant transcriptional programme by 
SESN3 in human TLE-hippocampus suggested a role for this gene in modulating seizures. 
To test the potential functional role of SESN3 in vivo, we used an experimental model of 
acute epileptic seizures34,37 and found that knockdown of Sesn3 attenuated chemical 
convulsant-induced locomotor activity and c-fos expression, as well as modulating 
Module-1 gene expression (Fig. 5). Our in vitro data in macrophages, BV2 microglial cells 
and primary neurons showed that SESN3 is a positive regulator of proinflammatory 
molecules (Fig. 4), including IL-1Ś and TNF-ř, major mediators of inflammation, which are 
capable of inducing changes in neuronal excitability50. The finding of reduced severity of 
PTZ-induced seizures upon knockdown of Sesn3 in the zebrafish model is consistent with 
previous studies in rodents describing the effects of proinflammatory cytokines on seizures. 
In the context of pre-existing brain inflammation, antibody-mediated antagonism of TNF-ř
function inhibited susceptibility to PTZ-induced seizures in rats51, whereas administration of 
exogenous TNF-ř increased susceptibility to PTZ-induced seizures52. Our findings in 
zebrafish are therefore in keeping with a role for SESN3 in regulating proinflammatory 
cytokines and their downstream effect on CNS excitability and seizure susceptibility.
Taken together, our data provide the first evidence of a function for SESN3 in regulating 
proconvulsant agents (for example, TNF-ř, IL-1 and TLR-signalling genes) in human 
epileptic hippocampus, and suggest SESN3 as a new potential target for modulating brain 
inflammation3,44 and CNS excitability53. Our systems genetics approach builds on and 
extends previous methods correlating individual genetic variation with disease susceptibility 
by identifying disease-associated gene networks, pathophysiological pathways and their 
upstream genetic regulators in human brain. More generally, the systems genetics 
framework described here can be employed to identify genes and regulatory networks across 
diverse neuropsychiatric disorders where genetic factors can perturb underlying molecular 
pathways in the brain.
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Methods
Gene expression profiling in the human hippocampus
All 129 patients considered in this study had mesial TLE and all tissue samples were from 
indistinguishable hippocampal tissue portions. Sample preparation and microarray analysis 
of human hippocampi are detailed in Supplementary Methods. Expression data were 
analysed using Illumina’ s GenomeStudio Gene Expression Module and normalized by 
quantile normalization with background subtraction. Microarray probes were annotated 
using either the Human HT-12 v3 annotation file or Ensembl (release 72). All patients gave 
informed consent for use of their tissue and all procedures were conducted in accordance 
with the Declaration of Helsinki and approved by the Ethics Committee of the University of 
Bonn Medical Center.
Gene co-expression network analysis
Gene co-expression networks were reconstructed using GGMs, which use partial 
correlations to infer co-expression relationships between any microarray probe pair in the 
data set, removing the effect of other probes23. We used the empirical Bayes local FDR 
statistics54 to extract significant partial correlations (Supplementary Fig. 13), and which 
identified a large set of 2,124 inter-connected nodes belonging to the same connected 
component (TLE-network, Supplementary Data 2). Network extraction and identification of 
transcriptional modules are described in the Supplementary Methods.
Mapping the genetic control of networks
We used Bayesian variable selection models18,29 to identify the genetic control points 
(regulatory ‘ hotspots’ ) of transcriptional modules in the TLE patient cohort. First, we 
combined PC analysis55 with multivariate regression approaches to prioritize genome-wide 
genomic regions associated with the module expression. We then analysed all genes of the 
module with all SNPs in the regulatory region using the hierarchical evolutionary stochastic 
search algorithm18, where the module genes’  expression are jointly considered. Further 
details are reported in Supplementary Methods.
Genetic association of the TLE-network with epilepsy
To test if TLE-network genes are likely to be causally involved in the disease process, we 
assessed whether network genes are enriched for SNP variants associated to focal epilepsy 
by GWAS6,25. Full details on the GWAS of focal epilepsy are reported in Supplementary 
Methods. Briefly, in the GWAS-enrichment analysis each gene of the TLE-network was 
assigned a GWAS significance value consisting of the smallest P-value of all SNPs mapped 
to it. We used the hypergeometric distribution test to assess whether SNPs close to (<100 kb 
from) any network gene were more likely to associate with epilepsy by GWAS than SNPs 
close to genes not in the TLE-network. Empirical GWAS-enrichment P-values were 
generated by 1,000,000 randomly selected gene-sets and are reported in Supplementary 
Table 2 (see Supplementary Methods for additional details).
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RNA-Seq analysis in the mouse hippocampus
RNA-Seq analysis in whole hippocampus from 100 epileptic (pilocarpine model)27 and 100 
control naïve mice (NMRI) is detailed in Supplementary Methods. Briefly, raw reads were 
mapped to the reference mouse genome (mm10) using TopHat version 2.0.8 (ref. 56) and 
read counts per gene were normalized across all samples using the ‘ trimmed mean of M-
value’  approach57. Differential expression analysis was performed using the edgeR57 and a 
threshold of 5% FDR was used to identify significant gene expression changes. 
Experimental animals were used only once for each study. All experimental procedures 
complied with the guidelines of the European Union Directive 2010/63/EU. A local ethical 
committee approved the experimental protocol.
In vitro studies
Details on all cell cultures used in these studies are reported in Supplementary Methods. 
SiRNA knockdown experiments were performed in murine BMDMs and BV2 microglia cell 
lines using a mouse Sesn3 ON-TARGETplus SMARTpool siRNA (100 nM, ThermoFisher 
Scientific) and Dharmafect 1 (ThermoFisher Scientific) as transfection reagent, according to 
the manufacturer’ s recommendations. For LPS stimulation experiments, the transfected cells 
were washed twice in DMEM and stimulated with LPS (Sigma, 100 ng ml−1) for an hour. 
For overexpression experiments, a third-generation LV was used to transduce murine 
primary hippocampal neuronal culture. Additional information and details on Sesn3 siRNA 
target sequences, the real-time quantitative PCR for Module-1 genes and primer sequences 
are given in Supplementary Methods and Supplementary Table 4. The relative expression 
levels normalized to Beta-actin (or Gapdh as indicated) gene expression were then 
determined by the 2−ΔΔCt method.
In vivo studies
To study the function of sestrin 3 in response to PTZ-induced seizures, two different 
morpholinos were designed to block the normal splicing of the zebrafish Sesn3 primary 
transcript (see Supplementary Fig. 12 and Supplementary Methods). Embryos that were to 
be analysed by whole-mount in situ hybridization were first treated with 1-phenyl-2 thiourea 
at 23 h post fertilization (h.p.f.) to inhibit melanogenesis. At 3 d.p.f., larvae were treated for 
1 h with 20 mM PTZ or left untreated, and all larvae were then fixed with paraformaldehyde 
immediately after the treatment period. RNA in situ hybridization analysis was carried out 
using a c-fos digoxigenin-labelled probe, which was prepared as recommended by the 
manufacturer of the in situ hybridization reagents (Roche). Whole-mount in situ 
hybridization was performed using standard procedures58. Analysis of zebrafish locomotor 
activity was carried out using the Viewpoint Zebrabox system (Viewpoint) as previously 
reported in ref. 34. Briefly, 3 d.p.f. larvae were incubated in E3 medium with or without 20 
mM PTZ in microtitre plates, with one larva per well, and larval movements were recorded 
with the Viewpoint Zebrabox over a recording period of 60 min, using a light cycle of 2 
min: 100% light; 2 min: 0% light. The distance swam by each larva was measured for every 
10-min period during the recording period, and the cumulative distance swam over the 
recording period was calculated. Rescue experiments were performed by co-injection of 
synthetic sesn3 RNA into one-cell stage AB wild-type zebrafish embryos alone (2 nl of 0.3 
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ng nl−1 sesn3 mRNA) or in combination with Sesn3 morpholinos. Additional details, 
including the quantitative PCR analyses of c-fos and Module-1 genes, primer sequences are 
reported in Supplementary Methods. All experimental procedures involving zebrafish were 
performed in compliance with the UK Animal (Scientific Procedures) Act and approved by 
the University of Sheffield Animal Welfare Ethical Review Board.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification of the TLE-network and functionally specialized transcriptional modules 
in human epileptic hippocampus
(a) Gene co-expression network identified in the hippocampus of TLE patients (TLE-
network). Nodes represent genes and edges represent significant partial correlations between 
their expression profiles (FDR<5%). Node colour indicates the best GWAS P-value of 
association with focal epilepsy for SNPs within 100 kb of each gene (Supplementary Data 
1). Boxes mark two transcriptional modules within the network. (b) Kyoto Encyclopedia of 
Genes and Genome (KEGG) pathways significantly enriched in the TLE-network 
(FDR<5%). The fold enrichment for each KEGG pathway is reported on the side of each 
bar. (c) Module-1 and Module-2 details. The size of each node is proportional to its degree 
of interconnectivity within each module. Light blue indicates genes showing nominal 
association with susceptibility to focal epilepsy by GWAS. Numbers in parenthesis indicate 
multiple microarray probes representing the same gene. (d) KEGG pathways significantly 
enriched in Module-1 (top) and Module-2 (bottom; FDR<5%). (e) Module-1 is significantly 
highly expressed in the hippocampus of TLE patients. mRNA expression of Module-1 (n = 
80 probes, representing 69 unique annotated genes) as compared with Module-2 (n = 60 
probes, representing 54 unique annotated genes), other network genes (n = 371 probes, 
representing 319 unique annotated genes) and all other probes represented on the microarray 
(n = 48,256). **P = 3.8 × 10−4; ***P < 10−10, Mann–Whitney test, two-tailed.
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Figure 2. TLE-network conservation in mouse epileptic hippocampus
(a) Human TLE-network genes that are conserved and co-expressed (84%) in the mouse 
hippocampus. Each node in the network represents a transcript that had significant partial 
correlation with at least another transcript in the network (FDR<5%). Conserved Module-1 
and Module-2 genes are indicated in blue and green, respectively. (b) Distribution of 
significant partial correlations (FDR<5%) between pairs of transcripts from 10,000 bootstrap 
permutation samples in epileptic (top) and control (bottom) mouse hippocampus. In each 
case, the red line indicates the actual number of significant partial correlations (FDR<5%) 
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between all genes in the network. The number of significant partial correlations observed in 
control hippocampus was no different from chance expectation (P = 0.659). In contrast, the 
number of significant partial correlations detected in epileptic hippocampus was 
significantly higher than expected by chance (P = 0.001). (c) Differential expression of 
Module-1 genes between control and epileptic mouse hippocampus shows specific 
enrichment for TLR-signalling and cytokine genes among the upregulated genes (gene set 
enrichment analysis28). Stars denote significant fold changes between epileptic and control 
mouse hippocampus (FDR<5%); blue bars indicate TLR-signalling and cytokine genes.
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Figure 3. SESN3 is a trans-acting genetic regulator of Module-1 in epileptic hippocampus
(a) Genome-wide mapping of the genetic regulation of Module-1. For each autosome 
(horizontal axis), the strength of evidence for each SNP (filled dot) being a regulatory locus 
for the first PC of Module-1 expression is measured by the log10(Bayes factor) (vertical 
axis). The Bayes factor quantifies evidence in favour of genetic regulation versus no genetic 
control of module expression, and is reported as a ratio between the strengths of these 
models. At 5% FDR (that is, log10(Bayes factor)>6, dashed line), SNP rs10501829 (11q21, 
highlighted in red) was significantly correlated with Module-1 expression. (b) Joint mRNA 
levels and SNPs analysis within the 1-Mbp region centred on SNP rs10501829, comprising 
178 SNPs genotyped in the TLE patient cohort. We carried out multivariate Bayesian 
regression modelling18 of all Module-1 probes (n = 80) and all SNPs (n = 178) to identify 
the most informative SNPs in the region predicting Module-1 expression. For each SNP, we 
report the proportion of associated genes in Module-1 (vertical axes): four SNPs 
(rs10501829, rs530190, rs7107661 and rs6483435) that are individually associated with 58–
74% of Module-1 genes are highlighted. The grey box indicates the boundaries of the 
associated regulatory region (delimited by SNPs rs530190 and rs6483435), spanning 383 kb. 
(c) For each candidate gene at the 1-Mbp regulatory locus, we report the average Pearson 
correlation (r; ± s.e.m.) between the candidate gene’ s expression and the expression of 
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Module-1 genes (y axes) and its statistical significance for deviation from r = 0 (x axes). 
Two-tailed P-values are reported on a negative log scale and were calculated using one 
sample Wilcoxon Signed Rank test. Two genes (ENDOD1 and MTMR2) were represented 
by two microarray probes and were analysed separately. (d) Association between increased 
Sesn3 mRNA expression and upregulation of Module-1 genes in epileptic mouse 
hippocampus. For each gene, we report its log10(fold change) in epilepsy versus control (y 
axes) and its correlation with Sesn3 mRNA expression (x axes). The 95% confidence 
interval of the slope of the regression line is indicated. TLR-signalling and cytokines genes 
are highlighted in blue.
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Figure 4. SESN3 regulates expression of Module-1 genes in macrophages, microglial cells and 
neurons
Effect of siRNA-mediated knockdown of Sesn3 as compared with control siRNA 
(siControl), showing significant inhibition of Sesn3 mRNA expression and downregulation 
of Module-1 genes in murine LPS-stimulated (1 h) BMDM (a) and BV2 microglial cells (b), 
as well as in unstimulated BV2 microglial cells (c). Five independent biological replicates 
were used for BMDM experiments and at least three replicates in the BV2 microglia cells 
experiments. Data normalized to Ś-actin levels are shown as means relative to control 
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±s.e.m. (d) SESN3 immunofluorescence of human hippocampal slices from TLE patients: 
co-immunostainings with NeuN (green) antibody showed that SESN3 (red) is localized in 
neurons. Scale bar, 100 μm. (e) Quantification of SESN3 expression in human hippocampal 
tissue by immunofluorescence analysis. Maximum intensity projections of confocal z-stack 
images of immunohistochemical stainings with antibody against SESN3 were used. For 
determination of SESN3 cell fluorescence as a measure of SESN3 expression level, SESN3-
expressing cells in the CA2 region of the hippocampus in both TLE patients samples (n = 7) 
and autopsy samples (n = 8) were measured using ImageJ software. Cell fluorescence was 
assessed as follows: integrated density— (area of selected cell × mean fluorescence of 
background readings). SESN3 total cell fluorescence in TLE patients is significantly 
increased as compared with the SESN3 total cell fluorescence in autopsy samples (two-
tailed Mann–Whitney test, P<0.001). Fluorescence intensity data are reported as means
±s.e.m. (f) Effect of lentiviral-mediated Sesn3 overexpression on Module-1 genes in primary 
hippocampal neurons. Left, relative levels of Sesn3 mRNA in transduced neurons (LV-
CMV-Sesn3) compared with the levels in mock transduction (Mock). Right, relative mRNA 
levels of Module-1 genes and a control gene not in the network (Hprt) in transduced neurons 
compared with levels in mock transduction. Data normalized to Gapdh levels are shown as 
means relative to control ±s.e.m. Four (Mock group) and twelve (LV-CMV-Sesn3 group) 
replicates were used in neuronal cell experiments. Statistical significance of the differences 
(P-value) between siSESN3 (or LV-CMV-Sesn3) and siControl (or Mock) was assessed by 
t-test (two-tailed) and adjusting for unequal variances across different groups. *P<0.05; 
**P<0.01; ***P<0.001; ****P<0.0001; NS, not significant (P>0.05).
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Figure 5. Sesn3 modulates PTZ-induced c-fos expression, locomotor convulsions and Module-1 
genes in zebrafish
(a) Left, Sesn3 promotes convulsive locomotor response of zebrafish larvae exposed to PTZ. 
Three days post fertilization (d.p.f.) zebrafish larvae were incubated with and without 20 
mM PTZ for 1 h and locomotor activity was monitored continuously. Larvae microinjected 
with Sesn3 morpholinos exhibited a sustained reduction in locomotor activity throughout the 
period of PTZ incubation, in comparison with control morphant larvae. Both Sesn3 
morphant and control morphant larvae (n = 12) exhibited similarly low levels of locomotor 
activity in the absence of PTZ. Right, Sesn3 morpholinos reduced the cumulative locomotor 
activity of zebrafish exposed to 20 mM PTZ (black columns) without appreciably affecting 
basal locomotor activity of larvae incubated in the absence of PTZ (white columns). (b) Co-
injecting Sesn3 morpholinos with synthetic Sesn3 mRNA showed that Sesn3 mRNA rescued 
the locomotor activity phenotype (total distance swam, y axis). For each group, 16–18 larvae 
were analysed. Black bars, 1 h PTZ treatment (20 mM). (c) Sesn3 morpholinos attenuate 
seizure-induced expression of the synaptic activity-regulated gene c-fos. Left and central 
images, dorsal views of the brains of 3 d.p.f. control morphant (top) and Sesn3 morphant 
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larvae (bottom) maintained for 1 h in the absence and presence of 20 mM PTZ, after which 
larvae were fixed and analysed for c-fos expression by whole-mount in situ hybridization. 
Red arrowheads: position of the transverse sections of the brains; scale bar, 200 μm. 
Following PTZ treatment (20 mM, 1 h), quantitative PCR (qPCR) analysis revealed that 
Sesn3 morphant larvae exhibited significantly lower mRNA expression of c-fos in the brain 
than control morphant larvae (c, right panel). (d) PTZ-induced transcriptional response of 
Module-1 genes was significantly lower in Sesn3 morphants as compared with uninjected 
larvae; six samples were used in the qPCR experiments (one sample = 15–20 pooled larvae). 
(e) Upregulation of Module-1 genes upon injection of synthetic mRNA (1 ng) in zebrafish 
embryos (n = 30) as compared with uninjected control embryos (n = 30). Total RNA was 
extracted 28 h post fertilization and qPCR experiments were performed for the two pools of 
embryos using six technical replicates. Data reported as means±s.e.m. were determined by 
the 2−ΔΔCt method and normalized to the housekeeping gene Ś-actin. P-values calculated by 
t-test (two-tailed) adjusting for unequal variances across different groups. NS, not significant 
(P>0.05).
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